Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK.

Med Pediatr Oncol. 2003 Dec;41(6):508-15.

PMID:
14595707
2.
3.

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ.

Med Pediatr Oncol. 2001 Jan;36(1):227-30.

PMID:
11464891
4.
6.

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM.

J Clin Oncol. 1998 Sep;16(9):3053-60.

PMID:
9738575
7.
8.

Chronic neuroblastoma.

Kushner BH, Kramer K, Cheung NK.

Cancer. 2002 Sep 15;95(6):1366-75.

9.

Neuroblastoma.

Meir HM, Balawi I, Nayel H, Yousef MK, Badawood S, Al-Mobarak M.

Saudi Med J. 2001 Aug;22(8):674-80.

PMID:
11573111
10.

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK.

J Clin Oncol. 2004 Dec 15;22(24):4888-92.

11.
12.

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK.

J Clin Oncol. 2003 Mar 15;21(6):1082-6.

PMID:
12637474
13.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807. Epub 2012 Aug 6.

14.

Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.

Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y.

Med Pediatr Oncol. 2001 Jan;36(1):203-4.

PMID:
11464885
15.

No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.

Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, Pecori E, Acerno S, Ferrari A, Terenziani M, Meazza C, Polastri D, Ravagnani F, Fossati-Bellani F.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1358-63. doi: 10.1016/j.ijrobp.2008.06.1930. Epub 2008 Nov 18.

PMID:
19019566
16.

Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.

Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NK.

J Clin Oncol. 2001 Jun 1;19(11):2821-8.

PMID:
11387353
17.

[Evaluation of efficacy of treatment for 30 children with neuroblastoma].

Sun XF, Liu DG, Su YS, Lin TY, Chen XQ, He YJ.

Ai Zheng. 2003 Dec;22(12):1343-5. Chinese.

PMID:
14693065
18.

Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).

Todeschini G, Tecchio C, Pasini F, Benedetti F, Cantini M, Crippa C, Draisci M, Pizzolo G.

Cancer. 2005 Aug 1;104(3):555-60.

19.

Local control with multimodality therapy for stage 4 neuroblastoma.

Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosen N, Abramson S, Cheung NV.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):969-74.

PMID:
10705019
20.

Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.

Frata P, Buglione M, Grisanti S, Bonetti B, Vitali E, De Stefani A, Magri E, Peveri A, Marini G, Rossi G, Magrini SM.

Tumori. 2005 Nov-Dec;91(6):456-62.

PMID:
16457141
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk